Copyright
©The Author(s) 2022.
World J Clin Oncol. Jun 24, 2022; 13(6): 448-472
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448
NCT | Phase | Study drugs | Treatment line | Endpoint | Estimated End of Trial |
NCT04194775 | 3 | CS1003 +LENVATINIB vs LENVATINIB | 1 | OS, PFS | June 2023 |
NCT04344158 | 3 | PENPULIMAB + ANLOTINIB vs SORAFENIB | 1 | OS | December 2024 |
NCT03713593 | 3 | PEMBROLIZUMAB + LENVATINIB vs LENVATINIB | 1 | OS, PFS | May 2022 |
NCT04411706 | 2 | SINTILIMAB + APATINIB + CAPECITABINE | 1 | ORR | June 2022 |
NCT04042805 | 2 | SINTILIMAB + LENVATINIB | 1 | ORR | August 2024 |
NCT04444167 | 2 | BISPECIFIC AK104 + LENVATINIB | 1 | ORR | March 2022 |
NCT04183088 | 2 | TISLELIZUMAB + REGORAFENIB | 1 | ORR, PFS, Safety | March 2025 |
NCT04310709 | 2 | NIVOLUMAB + REGORAFENIB | 1 | ORR | May 2023 |
NCT04442581 | 2 | PEMBROLIZUMAB + CABOZANTINIB | 1 | ORR | September 2024 |
NCT03439891 | 2 | NIVOLUMAB + SORAFENIB | 1 | MTD, ORR | May 2022 |
NCT04170556 | 2 | NIVOLUMAB + REGORAFENIB | 2 | Safety | December 2022 |
NCT04401800 | 1b/2 | TISLELIZUMAB + LENVATINIB | 1 | ORR | December 2022 |
NCT04443309 | 1b/2 | CAMRELIZUMAB + LENVATINIB | 1 | ORR | August 2024 |
NCT03347292 | 1 | PEMBROLIZUMAB + REGORAFENIB | 1 | DLT, Safety | October 2022 |
- Citation: Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472
- URL: https://www.wjgnet.com/2218-4333/full/v13/i6/448.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i6.448